drugset / Trial / NCT03750669
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend Nab-paclitaxel, Gemcitabine and modified Folfirinox as the first-line chemotherapeutic regimen. Studies have shown that sequential chemotherapeutic regimen can effectively delay the drug resistance and improve the effect of chemotherapy. Here investigators intend to assess the effect of sequential treatment with Nab-paclitaxel plus Gemcitabine and modified Folfirinox as neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma.
Timeline
- Start
- 2018-10-20
- Primary completion
- 2024-11-01
- Completion
- 2025-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 135 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 68 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |
| Background | folic acid | Other / unclassified | 400 mg/m2 | — |